NLRP3 and metabolic disease: CY-09 significantly ameliorates metabolic disorders in a diabetic mouse model (147), and can also alleviate inflammation, oxidative stress, and fibrosis in diabetic mice by selectively inhibiting NLRP3 inflammasome, thereby improving renal damage in diabetic nephropathy (149).